$PHAT
Phathom Pharmaceuticals, Inc.

2020 Q1 Form 10-K Financial Statement

#000156459020011712 Filed on March 19, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2018 Q4 2018 Q3
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.510M $440.0K $260.0K
YoY Change 463.75%
% of Gross Profit
Research & Development $15.87M $14.00K $6.000K
YoY Change 3598.14%
% of Gross Profit
Depreciation & Amortization $52.00K $0.00
YoY Change
% of Gross Profit
Operating Expenses $20.38M $451.0K $268.0K
YoY Change 1561.91%
Operating Profit -$20.38M -$451.0K -$268.0K
YoY Change 1561.91%
Interest Expense $738.0K -$10.00K $4.000K
YoY Change 6609.09%
% of Operating Profit
Other Income/Expense, Net $234.0K -$33.00K -$22.00K
YoY Change -1036.0%
Pretax Income -$20.14M -$480.0K -$290.0K
YoY Change 1511.2%
Income Tax
% Of Pretax Income
Net Earnings -$20.14M -$484.0K -$290.0K
YoY Change 1509.99%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$800.8K -$18.55K -$11.21K
COMMON SHARES
Basic Shares Outstanding 28.96M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2018 Q4 2018 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $256.7M
YoY Change
Cash & Equivalents $256.7M $879.0K
Short-Term Investments
Other Short-Term Assets $5.200M
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $261.8M $902.0K
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $1.700M
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $400.0K
YoY Change
Total Long-Term Assets $2.100M $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $261.8M $902.0K
Total Long-Term Assets $2.100M $0.00
Total Assets $263.9M $902.0K
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.200M $55.00K
YoY Change
Accrued Expenses $3.400M $170.0K
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.576M $2.188M
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $45.90M
YoY Change
Other Long-Term Liabilities $4.125M
YoY Change
Total Long-Term Liabilities $4.125M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.576M $2.188M
Total Long-Term Liabilities $4.125M
Total Liabilities $55.22M $2.188M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$276.6M -$1.288M
YoY Change
Common Stock $485.3M $2.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $208.7M -$1.286M -$802.0K
YoY Change
Total Liabilities & Shareholders Equity $263.9M $902.0K
YoY Change

Cashflow Statement

Concept 2020 Q1 2018 Q4 2018 Q3
OPERATING ACTIVITIES
Net Income -$20.14M -$484.0K -$290.0K
YoY Change 1509.99%
Depreciation, Depletion And Amortization $52.00K $0.00
YoY Change
Cash From Operating Activities -$11.42M -$300.0K -$270.0K
YoY Change 1314.75%
INVESTING ACTIVITIES
Capital Expenditures $676.0K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$676.0K $0.00 $0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 25.00M 1.050M 300.0K
YoY Change
NET CHANGE
Cash From Operating Activities -11.42M -300.0K -270.0K
Cash From Investing Activities -676.0K 0.000 0.000
Cash From Financing Activities 25.00M 1.050M 300.0K
Net Change In Cash 12.91M 750.0K 30.00K
YoY Change -1699.38%
FREE CASH FLOW
Cash From Operating Activities -$11.42M -$300.0K -$270.0K
Capital Expenditures $676.0K $0.00
Free Cash Flow -$12.09M -$270.0K
YoY Change 1398.51%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
100 Campus Drive
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 102
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
Florham Park
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07932
CY2019 dei City Area Code
CityAreaCode
877
CY2019 dei Local Phone Number
LocalPhoneNumber
742-8466
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
28964506
CY2019Q4 dei Entity Public Float
EntityPublicFloat
366400000
CY2019 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2019 dei Trading Symbol
TradingSymbol
PHAT
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
243765000
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2019 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2019 dei Entity File Number
EntityFileNumber
001-39094
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019 dei Entity Small Business
EntitySmallBusiness
true
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
879000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
23000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
902000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
463000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
11836000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
255601000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
933000
CY2018Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1950000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
635000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2063000
CY2019Q4 us-gaap Liabilities
Liabilities
29223000
CY2018Q4 us-gaap Liabilities
Liabilities
2188000
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
484372000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256419000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1288000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
227955000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-1286000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
257178000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
902000
CY2019Q4 phat Prepaid Expenses And Other Assets Related Parties Current
PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
0
CY2018Q4 phat Prepaid Expenses And Other Assets Related Parties Current
PrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
19000
CY2019Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
200000
CY2018Q4 us-gaap Accounts Payable Related Parties Current
AccountsPayableRelatedPartiesCurrent
45000
CY2019Q4 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
308000
CY2018Q4 phat Accrued Expenses Related Parties Current
AccruedExpensesRelatedPartiesCurrent
2000
CY2019Q4 phat Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
0
CY2018Q4 phat Accrued Interest Related Parties Current
AccruedInterestRelatedPartiesCurrent
13000
CY2019Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2018Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
1950000
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
20374000
CY2019 phat Process Research And Development
ProcessResearchAndDevelopment
78897000
CY2018 phat Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
50000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
11813000
CY2019 us-gaap Interest Expense Other
InterestExpenseOther
2605000
CY2019 phat Fair Value Adjustment Of Convertible Promissory Notes
FairValueAdjustmentOfConvertiblePromissoryNotes
49546000
CY2018 phat Change In Fair Value Of Convertible Promissory Notes
ChangeInFairValueOfConvertiblePromissoryNotes
-50000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-10000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-63000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-1288000
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.21
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6051675
CY2018 phat Research And Development Expense Related Party
ResearchAndDevelopmentExpenseRelatedParty
0
CY2018 phat General And Administrative Expense Related Party
GeneralAndAdministrativeExpenseRelatedParty
321000
CY2018 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
13000
CY2019 phat Change In Fair Value Of Warrant Liabilities Related Party
ChangeInFairValueOfWarrantLiabilitiesRelatedParty
96278000
CY2018 phat Change In Fair Value Of Warrant Liabilities Related Party
ChangeInFairValueOfWarrantLiabilitiesRelatedParty
0
CY2019 phat Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
10941000
CY2018 phat Change In Fair Value Of Convertible Promissory Notes Related Party
ChangeInFairValueOfConvertiblePromissoryNotesRelatedParty
50000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
0
CY2018 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
2000
CY2019 phat Adjustments To Additional Paid In Capital Conversion Of Warrant Liability Into Equity
AdjustmentsToAdditionalPaidInCapitalConversionOfWarrantLiabilityIntoEquity
144172000
CY2019 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
142437000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
406000
CY2019 us-gaap Profit Loss
ProfitLoss
-255131000
CY2018 us-gaap Profit Loss
ProfitLoss
-1288000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
8000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
406000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
409000
CY2019 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
78897000
CY2018 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
23000
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
2265000
CY2018 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
225000
CY2019 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
156000
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
13000
CY2019 phat Increase Decrease In Operating Right Of Use Asset And Lease Liabilities
IncreaseDecreaseInOperatingRightOfUseAssetAndLeaseLiabilities
51000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
181000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-36510000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1023000
CY2019 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
25118000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
132000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25250000
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
191472000
CY2018 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2000
CY2019 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
88324000
CY2018 us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
1900000
CY2019 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
24850000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
304646000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1902000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
242886000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
879000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
879000
CY2019 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
27000
CY2019 phat Issuance Of Common Stock Warrants In Connection With Long Term Debt
IssuanceOfCommonStockWarrantsInConnectionWithLongTermDebt
419000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
339000
CY2019 phat Non Cash Final Interest Payment Fee
NonCashFinalInterestPaymentFee
2063000
CY2019 phat Operating Lease Liabilities Arising From Obtaining Right Of Use Assets
OperatingLeaseLiabilitiesArisingFromObtainingRightOfUseAssets
796000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
243765000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
1007000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
142437000
CY2019 phat Non Cash Interest Expense Related Party
NonCashInterestExpenseRelatedParty
590000
CY2018 phat Non Cash Interest Expense Related Party
NonCashInterestExpenseRelatedParty
0
CY2019 phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
19000
CY2018 phat Increase Decrease In Prepaid Expenses And Other Assets Related Parties Current
IncreaseDecreaseInPrepaidExpensesAndOtherAssetsRelatedPartiesCurrent
-19000
CY2019 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
460000
CY2018 phat Increase Decrease In Accounts Payable And Accrued Expenses Related Parties
IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParties
47000
CY2019 phat Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
0
CY2018 phat Increase Decrease In Interest Payable Related Parties
IncreaseDecreaseInInterestPayableRelatedParties
13000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-top:10pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:10pt;margin-bottom:0pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of the Company&#8217;s combined financial statements requires it to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the Company&#8217;s combined financial statements and accompanying notes. The most significant estimates in the Company&#8217;s combined financial statements relate to accruals for research and development expenses, and the valuation of convertible promissory notes, warrant liabilities and various other equity instruments. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may undertake in the future, actual results could differ materially from those estimates and assumptions.</p>
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:10pt;text-indent:0%;font-style:italic;font-size:10pt;font-weight:bold;font-family:Times New Roman;text-transform:none;font-variant: normal;">Concentrations of Credit Risk</p> <p style="text-align:left;margin-bottom:0pt;margin-top:10pt;text-indent:5.24%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p>
CY2018 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
1,559.1183-for-1
CY2018 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1559.1183
CY2019Q4 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
2.168-for-1
CY2019Q4 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
2.168
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2019Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018Q4 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
0
CY2019 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2018 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Liability Transfers Out Of Level3
FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2019 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
796000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
471000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
8000
CY2019 us-gaap Depreciation
Depreciation
8000
CY2018 us-gaap Depreciation
Depreciation
0
CY2019 us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
CY2019Q4 phat Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
384000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
1052000
CY2018Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
76000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
478000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
94000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
405000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
166000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
171000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
176000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
181000
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
176000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
176000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2019 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
429000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
186000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
80000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
960000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
164000
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y3M29D
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0725
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
51000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
796000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
25000000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2223000
CY2019Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInNextTwelveMonths
1843000
CY2019Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearTwo
6609000
CY2019Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearThree
9533000
CY2019Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFour
8920000
CY2019Q4 phat Long Term Debt Maturities Repayments Of Principal And Interest In Year Five
LongTermDebtMaturitiesRepaymentsOfPrincipalAndInterestInYearFive
5599000
CY2019Q4 phat Long Term Debt And Interest
LongTermDebtAndInterest
32504000
CY2019Q4 phat Debt Instrument Interest And Final Payment Fee
DebtInstrumentInterestAndFinalPaymentFee
7504000
CY2019 phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vesting Restrictions Placed On Previously Issued Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestingRestrictionsPlacedOnPreviouslyIssuedShares
3373408
CY2019 phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Sale Of Unvested Common Stock
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsSaleOfUnvestedCommonStock
2524852
CY2019 phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Issuance Of Unvested Restricted Stock Awards
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsIssuanceOfUnvestedRestrictedStockAwards
16260
CY2019 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
17560
CY2019 phat Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Share Vesting
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsShareVesting
1660712
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
4236248
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
11974974
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1400528
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1400528
CY2019 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.10
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
9.10
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P0Y
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y8M8D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P0Y
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
30874000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
6800000
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y25D
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P0Y
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6017
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0158
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
406000
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-53578000
CY2018 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-271000
CY2019 phat Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
552000
CY2018 phat Income Tax Reconciliation Permanent Items
IncomeTaxReconciliationPermanentItems
2000
CY2019 phat Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt
IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt
30622000
CY2018 phat Income Tax Reconciliation Change In Fair Value Of Warrants And Convertible Debt
IncomeTaxReconciliationChangeInFairValueOfWarrantsAndConvertibleDebt
12000
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
697000
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
23046000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
257000
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
55000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
6322000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
5000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
204000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
16000
CY2019Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
16050000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2772000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4469000
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12704000
CY2019Q2 phat Process Research And Development
ProcessResearchAndDevelopment
78897000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
797000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1345000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1813000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2989000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
1226000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
83014000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
6282000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
15693000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1226000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-83014000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6282000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-15693000
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-251000
CY2018Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-255000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-268000
CY2018Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-451000
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000
CY2018Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
236000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
921000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
23497000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
257000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
23301000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
257000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
196000
CY2019Q4 us-gaap Deferred Tax Liabilities Other
DeferredTaxLiabilitiesOther
196000
CY2019Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-25000
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4748000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-61830000
CY2019Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-82313000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-1251000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-87762000
CY2018Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-22000
CY2018Q4 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-33000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-254000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-260000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-68112000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-98006000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-13.11
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-9.30
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.97
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6585503
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6694682
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
7326090
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-290000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-484000
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24706661
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6000
CY2018Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14000
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
251000
CY2018Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
255000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
262000
CY2018Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
437000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
251000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
255000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
268000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
451000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.07
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3886328
CY2018Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6760334
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6760334
CY2018Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6760334

Files In Submission

Name View Source Status
0001564590-20-011712-index-headers.html Edgar Link pending
0001564590-20-011712-index.html Edgar Link pending
0001564590-20-011712.txt Edgar Link pending
0001564590-20-011712-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
glm3ewvmpxov000001.jpg Edgar Link pending
glm3ewvmpxov000002.jpg Edgar Link pending
glm3ewvmpxov000003.jpg Edgar Link pending
glm3ewvmpxov000004.jpg Edgar Link pending
glm3ewvmpxov000005.jpg Edgar Link pending
glm3ewvmpxov000006.jpg Edgar Link pending
glm3ewvmpxov000007.jpg Edgar Link pending
glm3ewvmpxov000008.jpg Edgar Link pending
glm3ewvmpxov000009.jpg Edgar Link pending
glm3ewvmpxov000010.jpg Edgar Link pending
glm3ewvmpxov000011.jpg Edgar Link pending
glm3ewvmpxov000012.jpg Edgar Link pending
glm3ewvmpxov000013.jpg Edgar Link pending
glm3ewvmpxov000014.jpg Edgar Link pending
glm3ewvmpxov000015.jpg Edgar Link pending
glm3ewvmpxov000016.jpg Edgar Link pending
glm3ewvmpxov000017.jpg Edgar Link pending
glm3ewvmpxov000018.jpg Edgar Link pending
glm3ewvmpxov000019.jpg Edgar Link pending
glm3ewvmpxov000020.jpg Edgar Link pending
glm3ewvmpxov000021.jpg Edgar Link pending
glm3ewvmpxov000022.jpg Edgar Link pending
phat-10k_20191231.htm Edgar Link pending
phat-20191231.xml Edgar Link completed
phat-20191231.xsd Edgar Link pending
phat-20191231_cal.xml Edgar Link unprocessable
phat-20191231_def.xml Edgar Link unprocessable
phat-20191231_lab.xml Edgar Link unprocessable
phat-20191231_pre.xml Edgar Link unprocessable
phat-ex231_1348.htm Edgar Link pending
phat-ex311_919.htm Edgar Link pending
phat-ex312_918.htm Edgar Link pending
phat-ex321_916.htm Edgar Link pending
phat-ex322_917.htm Edgar Link pending
phat-ex46_1431.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending